覃江江
覃江江,中国科学院杭州医学研究所研究员,博士生导师,课题组长(PI),创新药物研究中心副主任。入选国家级青年人才项目,浙江省海外高层次人才,浙江省杰青等人才计划。主要研究领域为恶性肿瘤靶点发现与创新药物开发。近年以一作或通讯作者在Cancer Cell、Gastroenterology、Nature Communications、Cancer Research等期刊发表论文50余篇,被引用8000余次,H-Index为48,授权发明专利11项。获浙江省科技进步一等奖等省部级奖励3次。
2011.09-2014.09博士后-美国德州理工大学健;
2006.9-2011.7硕士/博士-上海交通大学-生物医学工程;
2002.9-2006.7本科-上海交通大学-药学
1)基于多组学的胃癌、胰腺癌等恶性肿瘤的新靶标发现与功能机制研究;
2)中药来源抗肿瘤活性成分发现与靶标机制研究;
3)基于新靶标与新机制的干预策略与创新药物研究
科技部重点研发、国自然基金、省自然重大、省杰青项目、省重点研发项目等10余项科研项目
近年以一作或通讯作者在Cancer Cell、Gastroenterology、Nature Communications、Cancer Research等期刊发表论文50余篇。
(1.) Atlas of metastatic gastric cancer links ferroptosis to disease progression and immunotherapy response. Gastroenterology 2024;
(2.)Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression. Cancer Cell 2023;
(3.) Integrated proteogenomic characterization of adenocarcinoma of esophagogastric junction. Nature Communications 2023;
(4.) METI: Deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomics. Nature Communications 2024;
(5.) Blocking Ubiquitin-Specific Protease 7 Induces Ferroptosis in Gastric Cancer via Targeting Stearoyl-CoA Desaturase. Advanced Science 2024;
(6.) Heat Shock Protein 90 Interactome-Mediated Proteolysis Targeting Chimera (HIM-PROTAC) Degrading Glutathione Peroxidase 4 to Trigger Ferroptosis. Journal Medicinal Chemistry 2024;
(7.) Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nature Medicine 2023;
(8.)Targeting E2 ubiquitin-conjugating enzyme UbcH5c by small molecule inhibitor suppresses pancreatic cancer growth and metastasis. Molecular Cancer 2022
(1.) 2022年浙江省科技进步一等奖;
(2.) 一种具有抗肿瘤活性的嗜氮酮生物碱、制备方法及其用途, CN202010078082.7;
(3.) 一种具有抗肿瘤活性的苯并二呋喃酮类化合物、制备方法及其用途, CN202010439985.3;
(4.) 用于靶向抑制GPX4的醌类化合物及其制备方法和应用, CN202211439020.X;
(5.) 一种靶向降解GPX4的PROTAC嵌合体及其制备方法和应用, CN202211316429.2;
(6.) 一种基于分子伴侣HSP90 介导的靶向降解GPX4 的嵌合体及其制备方法和应用, CN2023105746296;
(7.) 一种基于HSP90 蛋白靶向降解GPX4 的嵌合体及制备方法和应用, CN2023105790833